Lobular breast carcinoma in situ
MONDO:0006270A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina. The overall lobular architecture is preserved. It is frequently multifocal (90% in some series) and bilateral. It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.
Also known as: LCIS, lobular Ca in situ of breast, lobular Ca in situ of the breast, lobular breast carcinoma in situ, lobular carcinoma in situ, lobular carcinoma in situ (LCIS), lobular carcinoma in situ of breast, lobular carcinoma in situ of the breast
2840 clinical trials for this condition and its sub-types, 27 tagged with Lobular breast carcinoma in situ itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New shot aims to stop breast cancer before it starts
Disease control Not yet recruitingThis early-phase trial tests a drug called CAN1012 in 24 people with pre-cancerous breast conditions (DCIS or LCIS). The drug is injected directly into the lesion to activate the immune system. The main goal is to check safety and ensure the treatment doesn't delay necessary surg…
Phase 1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Surgery-free breast cancer treatment tested in new trial
Disease control Not yet recruitingThis study is testing whether people with certain non-invasive or early breast conditions (like ductal carcinoma in situ) can safely skip surgery and instead take hormone-blocking medication. The goal is to see if this approach keeps cancer from coming back over five years. The t…
Sponsor: Jeong Eon Lee • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a 'Baby Dose' of hormone pills prevent breast cancer?
Prevention Not yet recruitingThis study tests whether low doses of two hormone-blocking drugs, exemestane and tamoxifen, can help prevent breast cancer in postmenopausal women at high risk. About 140 women will take one of the two drugs for a year, and researchers will measure side effects and quality of lif…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC